tafluprost

REMS

Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Contraindicated in:

Pedi: Avoid use in children due to unknown safety of chronic ↑ pigmentation.

Use Cautiously in:

Aphakia, pseudoaphakia with a torn posterior lens capsule;
Known risk factors for macular edema;
OB: Women with child-bearing potential should practice adequate contraception;
Lactation: Use cautiously in nursing women.

EENT: conjunctival hyperemia, blurred vision, cataract, eyelid pigmentation, lash pigmentation/increased thickness/↑ number, macular edema, ocular stinging/irritation, permanent iris pigmentation

Drug-drug:

Note noted.

Ophthalmic solution : 0.0015% in 0.3 mL single-use containers

(Adults ): One drop once daily (into conjunctival sac) in the evening into affected eye(s).

Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.

Therapeutic effects:

↓intraocular pressure.

Therapeutic Classification: ocular hypotensive agent

Pharmacologic Classification: prostaglandins

Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.

Distribution: Unknown.

Metabolism/Excretion: Further metabolized and eliminated.

Half-Life: Unknown.

(↓ in intraocular pressure)

ROUTE	ONSET	PEAK	DURATION
Ophth	within 2–4 hr	12 hr	24 hr

Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.

NDC Code

0781- Sandoz Inc
- 0781-6184- Tafluprost
  - 0781-6184-87- 6 POUCH in 1 CARTON (0781-6184-87) / 5 CONTAINER in 1 POUCH (0781-6184-14) / .3 mL in 1 CONTAINER

50742- Ingenus Pharmaceuticals, LLC
- 50742-339- Tafluprost
  - 50742-339-30- 6 POUCH in 1 CARTON (50742-339-30) / 5 VIAL, SINGLE-DOSE in 1 POUCH (50742-339-05) / .3 mL in 1 VIAL, SINGLE-DOSE

54893- MSN Laboratories Private Limited
- 54893-0021-
  - 54893-0021-6- 3 kg in 1 DRUM (54893-0021-6)

61556- Cayman Pharma s.r.o.
- 61556-080-
  - 61556-080-00- 80 g in 1 BOTTLE (61556-080-00)

63190- Industriale Chimica s.r.l.
- 63190-0590-
  - 63190-0590-5- 25 kg in 1 DRUM (63190-0590-5)

65035- Everlight Chemical Industrial Corporation Kuanyin II Plant
- 65035-137-
  65035-137-01- 1 g in 1 BOTTLE (65035-137-01)

65035- Everlight Chemical Industrial Corporation Kuanyin II Plant
- 65035-137-
  65035-137-02- 2 g in 1 BOTTLE (65035-137-02)

65035- Everlight Chemical Industrial Corporation Kuanyin II Plant
- 65035-137-
  65035-137-05- 5 g in 1 BOTTLE (65035-137-05)

65035- Everlight Chemical Industrial Corporation Kuanyin II Plant
- 65035-137-
  65035-137-10- 10 g in 1 BOTTLE (65035-137-10)

65035- Everlight Chemical Industrial Corporation Kuanyin II Plant
- 65035-137-
  65035-137-50- 50 g in 1 BOTTLE (65035-137-50)

65035- Everlight Chemical Industrial Corporation Kuanyin II Plant
- 65035-137-
  65035-137-85- 85 g in 1 BOTTLE (65035-137-85)

66993- Prasco Laboratories
- 66993-429- Tafluprost Ophthalmic
  66993-429-30- 3 POUCH in 1 CARTON (66993-429-30) / 10 VIAL, SINGLE-USE in 1 POUCH (66993-429-81) / .3 mL in 1 VIAL, SINGLE-USE

68245- Chirogate International Inc
- 68245-0012-
  - 68245-0012-1- 5 g in 1 VIAL, GLASS (68245-0012-1)

68245- Chirogate International Inc
- 68245-0012-
  68245-0012-2- 15 g in 1 VIAL, GLASS (68245-0012-2)

68245- Chirogate International Inc
- 68245-0012-
  68245-0012-3- 25 g in 1 VIAL, GLASS (68245-0012-3)

68245- Chirogate International Inc
- 68245-0012-
  68245-0012-4- 50 g in 1 VIAL, GLASS (68245-0012-4)

68245- Chirogate International Inc
- 68245-0012-
  68245-0012-5- 100 g in 1 VIAL, GLASS (68245-0012-5)

70390- AGC WAKASA CHEMICALS CO., LTD.
- 70390-0001-
  70390-0001-1- 2 g in 1 VIAL (70390-0001-1)

75872- AGC Inc.
- 75872-0001-
  75872-0001-1- 2 g in 1 VIAL (75872-0001-1)

76397- Zhejiang Ausun Pharmaceutical Co., Ltd.
- 76397-013-
  76397-013-07- 20 g in 1 BAG (76397-013-07)

76397- Zhejiang Ausun Pharmaceutical Co., Ltd.
- 76397-013-
  76397-013-08- 100 g in 1 BAG (76397-013-08)

82584- Thea Pharma Inc.
- 82584-609- ZIOPTAN
  82584-609-30- 3 POUCH in 1 CARTON (82584-609-30) / 10 VIAL, SINGLE-USE in 1 POUCH (82584-609-01) / .3 mL in 1 VIAL, SINGLE-USE

section name header

Indications ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Availability ⬆ ⬇

Route/Dosage ⬆ ⬇

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Classifications ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

Code ⬆